HK1171390A1 - Heparanase activity inhibitor - Google Patents

Heparanase activity inhibitor

Info

Publication number
HK1171390A1
HK1171390A1 HK12112298.0A HK12112298A HK1171390A1 HK 1171390 A1 HK1171390 A1 HK 1171390A1 HK 12112298 A HK12112298 A HK 12112298A HK 1171390 A1 HK1171390 A1 HK 1171390A1
Authority
HK
Hong Kong
Prior art keywords
activity inhibitor
heparanase activity
heparanase
inhibitor
activity
Prior art date
Application number
HK12112298.0A
Other languages
English (en)
Inventor
Shunsuke Iriyama
Hirotada Fukunishi
Masaru Suetsugu
Satoshi Amano
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Publication of HK1171390A1 publication Critical patent/HK1171390A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
HK12112298.0A 2009-09-30 2012-11-29 Heparanase activity inhibitor HK1171390A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009228406 2009-09-30
PCT/JP2010/066998 WO2011040496A1 (fr) 2009-09-30 2010-09-29 Inhibiteur de l'activité héparanase

Publications (1)

Publication Number Publication Date
HK1171390A1 true HK1171390A1 (en) 2013-03-28

Family

ID=43826308

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12112298.0A HK1171390A1 (en) 2009-09-30 2012-11-29 Heparanase activity inhibitor

Country Status (12)

Country Link
US (2) US8609075B2 (fr)
EP (1) EP2484359B1 (fr)
JP (2) JP5593323B2 (fr)
KR (1) KR101431348B1 (fr)
CN (1) CN102655863B (fr)
BR (1) BR112012007090A2 (fr)
ES (1) ES2687780T3 (fr)
HK (1) HK1171390A1 (fr)
IN (1) IN2012DN02632A (fr)
RU (1) RU2503454C1 (fr)
TW (1) TWI461221B (fr)
WO (1) WO2011040496A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5685369B2 (ja) * 2009-09-15 2015-03-18 株式会社 資生堂 ヘパラナーゼ阻害剤による美白方法及び美白効果を有する物質の評価方法
JP2013032332A (ja) * 2011-07-01 2013-02-14 Lintec Corp 免疫賦活剤
JP5258993B1 (ja) * 2012-03-29 2013-08-07 株式会社 資生堂 ヘパラン硫酸産生促進剤
JP6321506B2 (ja) * 2014-09-22 2018-05-09 株式会社 資生堂 ヘパラナーゼ阻害剤による美白方法及び美白効果を有する物質の評価方法
CN109844128A (zh) 2016-10-21 2019-06-04 株式会社资生堂 层粘连蛋白511产生促进剂、表皮基底膜稳定剂和/或表皮干细胞减少抑制或增加促进剂的筛选方法
JP2020503377A (ja) 2016-12-13 2020-01-30 ベータ セラピューティクス プロプライアタリー リミティド ヘパラナーゼ阻害剤及びそれの使用
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
EP3381908A1 (fr) 2017-03-27 2018-10-03 Leadiant Biosciences SA Dérivés de benzazole 2-(4-(4-(bromo-methoxybenzamido)benzylamino)phényl) et leur utilisation comme anti-héparanase
EP3381898A1 (fr) 2017-03-27 2018-10-03 Leadiant Biosciences SA Derives de tris-aryl-amides symmmetriques et leur utilisation en tant qu'anti-heparanase
EP3381907A1 (fr) 2017-03-27 2018-10-03 Leadiant Biosciences SA Composés de 2-aminophényl-benzazolyl-5-acétate symétriques et leur utilisation comme anti-héparanase
EP3381897A1 (fr) 2017-03-27 2018-10-03 Leadiant Biosciences SA Dérivés du sel de disodium 2,2'-{carbonylbis[imino-3,1-phénylenecarbonylimino(1-méthyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalène-1,5-disulfonate et composés similaires en tant qu'inhibiteurs d'héparanase pour le traitement du cancer
EP3381906A1 (fr) 2017-03-27 2018-10-03 Leadiant Biosciences SA Composes utiles comme inhibiteurs d'heparanase
EP3388439A1 (fr) 2017-04-11 2018-10-17 Leadiant Biosciences SA Héparine divisée de n-acétyl glycol conjuguée à la biotine
WO2018230537A1 (fr) 2017-06-13 2018-12-20 国立研究開発法人国立がん研究センター Inhibiteur de la carcinogenèse
US20220202964A1 (en) * 2019-04-24 2022-06-30 University Of Florida Research Foundation, Incorporated Heparanase compounds and methods of use
CN116710048A (zh) 2020-12-15 2023-09-05 株式会社资生堂 表皮干细胞增加促进剂
WO2022131108A1 (fr) * 2020-12-15 2022-06-23 株式会社 資生堂 Promoteur de régénération de derme
CN118201596A (zh) 2021-12-02 2024-06-14 株式会社资生堂 化妆品
WO2023100682A1 (fr) * 2021-12-03 2023-06-08 株式会社 資生堂 Produit cosmétique
CN118251204A (zh) * 2021-12-09 2024-06-25 株式会社资生堂 化妆品
WO2023106121A1 (fr) * 2021-12-09 2023-06-15 株式会社 資生堂 Cosmétique en émulsion huile dans l'eau
WO2023120180A1 (fr) * 2021-12-20 2023-06-29 株式会社 資生堂 Produit cosmétique émulsifié de type huile dans l'eau
WO2023149225A1 (fr) * 2022-02-03 2023-08-10 株式会社 資生堂 Composition de soins de la peau

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1256235A (en) * 1917-03-31 1918-02-12 William F Jacobs Work-supporting horse.
US4049650A (en) 1976-10-18 1977-09-20 Morton-Norwich Products, Inc. 1-[[[5-(Substituted phenyl)-2-oxazolyl]methylene]amino]-2,4-imidazolidinediones
US4593038A (en) * 1985-04-03 1986-06-03 Burzynski Stanislaw R Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation
US4731453A (en) 1985-04-03 1988-03-15 Mitsui Toatsu Chemicals, Inc. Process for producing 1, 3-dialkyl-2-imidazolidinone
US4960771A (en) 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5011621A (en) 1990-06-04 1991-04-30 Arco Chemical Technology, Inc. Paint stripper compositions containing N-methyl-2-pyrrolidone and renewable resources
US5583256A (en) 1994-07-07 1996-12-10 Mitsui Toatsu Chemicals, Inc. Process for producing 1,3-dialkyl-2-imidazolidinone
US5536740A (en) * 1995-06-01 1996-07-16 Elizabeth Arden Company, Division Of Conopco, Inc. Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester
US5837224A (en) 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
JPH11335235A (ja) 1998-05-22 1999-12-07 Shiseido Co Ltd 抗老化剤
GB9913415D0 (en) 1999-06-10 1999-08-11 Central Manchester Healthcare Heparanase assay
JP2001163794A (ja) 1999-12-03 2001-06-19 Shiseido Co Ltd ヒアルロン酸産生促進剤および皮膚外用剤
TWI233361B (en) 2001-04-13 2005-06-01 Gen Hospital Corp Methods of preventing UVB-induced skin damage
US20030129259A1 (en) * 2001-12-28 2003-07-10 Avon Products, Inc. Topical lightening compostitions and methods of use
DE50203746D1 (de) * 2002-02-15 2005-09-01 Goldschmidt Gmbh Verwendung von Kreatinin und/oder Kreatinin-Derivaten zur Aufhellung der Haut und Milderung von Pigmentstörungen
KR100920961B1 (ko) 2002-06-25 2009-10-09 가부시키가이샤 시세이도 항노화제
KR20060097000A (ko) * 2003-09-23 2006-09-13 노파르티스 아게 화학요법제와 vegf 수용체 저해제의 배합물
AU2004293443A1 (en) * 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc. Indazole Compounds and methods of use thereof as protein kinase inhibitors
FR2873377B1 (fr) * 2004-07-23 2006-10-13 Sanofi Synthelabo Derives d'azasucre, inhibiteurs d'heparanases, leur procede de preparation, les compositions en contenant et leur utilisation
US7238260B2 (en) 2004-10-26 2007-07-03 Lyondell Chemical Technology, L.P. Purification of N-(2-hydroxyethyl)-2-pyrrolidone
JP2006303185A (ja) 2005-04-20 2006-11-02 Matsushita Electric Ind Co Ltd 半導体装置及びその製造方法
JP2007277149A (ja) 2006-04-06 2007-10-25 Kao Corp インボルクリン発現促進剤
US8097581B2 (en) 2007-05-10 2012-01-17 Grant Industries Inc. Anti-wrinkle cosmetic composition
CN101311188B (zh) * 2007-05-21 2010-12-29 中国人民解放军军事医学科学院生物工程研究所 人乙酰肝素酶的小分子多肽抑制剂
JP2008303187A (ja) * 2007-06-08 2008-12-18 Shiseido Co Ltd コーニファイドエンベロープ形成・成熟化促進剤
JP5179096B2 (ja) * 2007-06-08 2013-04-10 株式会社 資生堂 コーニファイドエンベロープ形成・成熟化促進剤
JP5105962B2 (ja) * 2007-06-08 2012-12-26 株式会社 資生堂 コーニファイドエンベロープ形成・成熟化促進剤
EP2295028A4 (fr) * 2008-03-31 2013-11-13 Shiseido Co Ltd Préparation destinée à prévenir ou à améliorer les rides, devant être prise par voie orale, par injection ou par application cutanée externe, et procédé cosmétique
WO2009122540A1 (fr) * 2008-03-31 2009-10-08 株式会社資生堂 Agent de prévention ou d’amélioration de rides pour administration orale, injection ou application externe à la peau et procédé cosmétique
FR2931064B1 (fr) 2008-05-14 2010-08-13 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone; procede de photostabilisation du derive de dibenzoylmethane

Also Published As

Publication number Publication date
CN102655863B (zh) 2013-11-20
TWI461221B (zh) 2014-11-21
ES2687780T3 (es) 2018-10-29
CN102655863A (zh) 2012-09-05
EP2484359A4 (fr) 2015-07-08
BR112012007090A2 (pt) 2018-06-05
KR101431348B1 (ko) 2014-08-19
US20140080878A1 (en) 2014-03-20
JP2014111640A (ja) 2014-06-19
US20120183481A1 (en) 2012-07-19
RU2503454C1 (ru) 2014-01-10
TW201117832A (en) 2011-06-01
IN2012DN02632A (fr) 2015-09-04
JPWO2011040496A1 (ja) 2013-02-28
KR20120060205A (ko) 2012-06-11
AU2010301641A1 (en) 2012-03-22
JP5593323B2 (ja) 2014-09-24
US8609075B2 (en) 2013-12-17
EP2484359A1 (fr) 2012-08-08
US8901160B2 (en) 2014-12-02
EP2484359B1 (fr) 2018-07-25
RU2012117797A (ru) 2013-11-10
WO2011040496A1 (fr) 2011-04-07

Similar Documents

Publication Publication Date Title
HK1171390A1 (en) Heparanase activity inhibitor
EP2391623A4 (fr) Inhibiteurs de l'activité d'akt
EP2409270A4 (fr) Alerte d'activité de compte
HK1204227A1 (en) Benzamide derivatives
EP2443235A4 (fr) Variants de -glucosidase
EP2413932A4 (fr) Inhibiteurs de l'activité akt
EP2406250A4 (fr) Inhibiteurs de l'activité akt
EP2389068A4 (fr) Inhibiteurs de la voie hedgehog
IL220526A0 (en) Kokumi-imparting agent
EP2478768A4 (fr) Agent antiphytoviral
IL220527A0 (en) Kokumi-imparting agent
EP2519508A4 (fr) Composés inhibiteurs de métallo-enzyme
EP2405756A4 (fr) Inhibiteurs de l'activité akt
HK1171013A1 (en) Inhibitors of akt activity akt
EP2514426A4 (fr) Composés à activité anti-inflammatoire
GB0901898D0 (en) Dual calpain-ros inhibitors
GB0907886D0 (en) Corrosion inhibitor
EP2496230A4 (fr) Inhibiteurs de l'ire-1 alpha
EP2433502A4 (fr) Agent de suppression d'amertume
GB0901900D0 (en) Dual calpain-ros inhibitors
EP2463292A4 (fr) Composé ayant une activité d excroissance des neurites
AU2010301641B2 (en) Heparanase activity inhibitor
EP2434392A4 (fr) Processeur
GB0906509D0 (en) Wok stabiliser
GB0906919D0 (en) Inhibitor complex structure

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210925